US 12,303,592 B2
Formulations for parenteral delivery of compounds and uses thereof
Syed M. Shah, Delray Beach, FL (US); Christian Ofslager, Newburgh, NY (US); Mahdi B. Fawzi, Morristown, NJ (US); and Nataliya Bazhina, Tappan, NY (US)
Assigned to Wyeth, LLC, Madison, NJ (US)
Filed by Wyeth, LLC, Madison, NJ (US)
Filed on Sep. 11, 2023, as Appl. No. 18/244,446.
Application 18/244,446 is a continuation of application No. 17/357,023, filed on Jun. 24, 2021, abandoned.
Application 17/357,023 is a continuation of application No. 16/514,722, filed on Jul. 17, 2019, abandoned.
Application 16/514,722 is a continuation of application No. 15/158,967, filed on May 19, 2016, abandoned.
Application 15/158,967 is a continuation of application No. 14/105,805, filed on Dec. 13, 2013, abandoned.
Application 14/105,805 is a continuation of application No. 12/726,113, filed on Mar. 17, 2010, abandoned.
Application 12/726,113 is a continuation of application No. 11/890,034, filed on Aug. 3, 2007, abandoned.
Claims priority of provisional application 60/835,574, filed on Aug. 4, 2006.
Prior Publication US 2023/0414490 A1, Dec. 28, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 31/485 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01)
CPC A61K 9/0019 (2013.01) [A61K 31/485 (2013.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01)] 19 Claims
 
1. A pharmaceutical composition comprising an effective amount of methylnaltrexone or a pharmaceutically acceptable salt thereof, about 0.4 mg/mL of calcium ethylenediaminetetraacetic acid (EDTA) disodium, and about 0.1 mg/mL to about 0.8 mg/mL of glycine in an aqueous solution, wherein the solution has a pH of about 3 to 4.